ORIC Pharmaceuticals (ORIC) Projected to Post Quarterly Earnings on Monday
ORIC Pharmaceuticals (NASDAQ:ORIC – Get Free Report) is expected to post its quarterly earnings results before the market ...
TipRanks on MSN4d
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
Oric Pharmaceuticals ( ($ORIC) ) has provided an announcement. On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment ...
Hosted on MSN14d
ORIC Pharmaceuticals stock target holds at $21 by H.C. Wainwright
On Tuesday, H.C. Wainwright research firm maintained a positive outlook on ORIC Pharmaceuticals (NASDAQ:ORIC), reiterating a Buy rating and a $21.00 price target for the company's stock.
Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)
Oppenheimer analyst Matthew Biegler reiterated a Buy rating on Olema Pharmaceuticals (OLMA – Research Report) yesterday and set a price target ...
ETF Daily News23d
ORIC Pharmaceuticals’ (ORIC) Buy Rating Reiterated at HC Wainwright
Shares of ORIC stock opened at $7.68 on Friday. ORIC Pharmaceuticals has a 1-year low of $6.33 and a 1-year high of $16.65. The firm’s 50-day simple moving average is $9.27 and its 200-day ...
Morningstar29d
ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates
and SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of ...
Nasdaq28d
ORIC Pharmaceuticals Reports Promising Early Data for ORIC-944 and ORIC-114; Collaborates with Johnson & Johnson on NSCLC Treatment
ORIC Pharmaceuticals, Inc. announced positive early safety and efficacy results from its ongoing dose escalation trial of ORIC-944, combined with androgen receptor inhibitors for metastatic ...